Skip to main content

Table 3 Summary of Week 12 and Week 52 predictive factors of response in CZP-treated patients

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

Response Week 12 Week 52
ASDAS-MI - Younger age
- Male sex
- Elevated CRP
- Higher PtGADA at baseline
- MRI+/HLA-B27+
- Higher BASDAI at baseline
- Greater Week 12 ASDAS improvement
ASAS40 - Younger age
- Male sex
- MRI+/HLA-B27+
- Lower BASMI at baseline
- Greater Week 12 PtGADA and ASQoL improvements
BASDAI50 - Younger age
- Male sex
- MRI+/HLA-B27+
- MASES = 0
- Greater Week 12 BASDAI and ASQoL improvements
ASDAS-ID - Younger age
- Male sex
- Positive MRI
- ≤2 prior NSAIDs
- ASDAS-ID at Week 12
- Lower BASFI at baseline
- Greater Week 12 BASDAI improvement
  1. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), ASQoL Ankylosing Spondylitis Quality of Life, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, BASMI Bath Ankylosing Spondylitis Metrology Index, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging, MASES Maastricht Ankylosing Spondylitis Enthesitis Score (range 0−13), NSAID non-steroidal anti-inflammatory drug, PtGADA Patient Global Assessment of Disease Activity